Transocean Ltd. (RIG) Pops 2.9% for February 15

Equities Staff |

One of the S&P 500’s big winners for Monday February 15 was Transocean Ltd. (RIG) as the company’s stock climbed 2.9% to $8.86 on volume of 12.11 million shares.

The stock opened at $8.91 and saw an intraday low of $8.57 and an intraday high of $9.16. All told, the day saw a per-share gain of $0.25. The stock’s average daily volume of 11.4 million and 363.74 million shares outstanding. Transocean Ltd. now has a 50-day SMA is $11.22 and 200-day SMA is $14.41, and it has a 52-week high of $21.90 and a 52-week low of $8.23.

Transocean Ltd is an international provider of offshore contract drilling services for oil and gas wells. The Company has two operating segments; contract drilling services and drilling management services.

Based out of Vernier, , Transocean Ltd. has 13,100 employees and, after today’s trading, reached a market cap of $3.22 billion. Its P/S ratio is 0.57, P/B ratio is 0.24, and P/FCF ratio is 2.8.

For a complete fundamental analysis analysis of Transocean Ltd., check out’s Stock Valuation Analysis report for RIG. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…